Cinolazepam

Clinical data
Trade names	Gerodorm
AHFS/Drugs.com	cinolazepam
Routes of administration	Oral
ATC code	N05CD13 (WHO)
Legal status
Legal status	US: Unscheduled
Pharmacokinetic data
Bioavailability	90–100%
Metabolism	Hepatic
Elimination half-life	3.8 hours[1]
Excretion	Renal
Identifiers
IUPAC name (RS)-3-[9-Chloro-6-(2-fluorophenyl)-4-hydroxy-3-oxo-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen-2-yl]propanenitrile
CAS Number	75696-02-5 Y
PubChem CID	3033621
DrugBank	DB01594 Y
ChemSpider	2298251 Y
UNII	68P0556B0U
KEGG	D07328 Y
ChEBI	CHEBI:59514 Y
ChEMBL	ChEMBL2104926 N
CompTox Dashboard (EPA)	DTXSID30868372
Chemical and physical data
Formula	C18H13ClFN3O2
Molar mass	357.77 g·mol−1
3D model (JSmol)	Interactive image
Chirality	Racemic mixture
SMILES FC1=CC=CC=C1C2=NC(C(N(CCC#N)C3=C2C=C(C=C3)Cl)=O)O
InChI InChI=1S/C18H13ClFN3O2/c19-11-6-7-15-13(10-11)16(12-4-1-2-5-14(12)20)22-17(24)18(25)23(15)9-3-8-21/h1-2,4-7,10,17,24H,3,9H2 Y Key:XAXMYHMKTCNRRZ-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Cinolazepam^[2] (marketed under the brand name Gerodorm)^[3] is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Due to its strong sedative properties, it is primarily used as a hypnotic.

It was patented in 1978 and came into medical use in 1992.^[4] Cinolazepam is not approved for sale in the United States or Canada.